A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
The large-scale phase IV study aims to verify the safety and efficacy of apatinib in patients
with advanced gastric cancer or gastroesophageal junction adenocarcinoma after failure of two
lines of chemotherapy. Apatinib initiated at a recommended dose of 850mg. However, the
starting dose was decided by investigator's choice based on patients' condition. Dose
interruption and dose reduction were allowed according to the product label. Treatment
continued until disease progression, intolerable toxicity, withdrawal of informed consent, or
at investigators' discretion. The primary endpoint was safety, which was assessed by
recording the incidence and severity of adverse events.